In Brief: ELA Medical
This article was originally published in The Gray Sheet
Executive Summary
ELA Medical: U.S. clinical trials commence for the Defender II dual-chamber pacer/implantable cardioverter defibrillator following FDA clearance of an investigational device exemption covering 50 patients at 10 centers. Using ELA's Parad algorithm, the Defender II takes readings from the atrium and the ventricle for enhanced arrhythmia detection to reduce the incidence of inappropriate therapies, the firm maintains...